CLINICAL_TRIALS
trial_result
· 2025-02-05
Clinical Trial Update: A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD [Phase 3]
Summary
A completed Phase 3 trial evaluating TNX-102 SL 5.6 mg taken at bedtime for post-traumatic stress disorder has posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 3 | Status: COMPLETED | Results posted: 2025-02-05